Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The legal team said the jury's decision could make medics think twice before allowing the injured to return to the field.
Read Full NewsA nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.
The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.
Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.
REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis
1.
Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group
2.
Distinct results for patients with positive and negative pancreatic cancer who are treated with systemic therapy, chemotherapy, and radiation.
3.
FDA Expands Approval of Osimertinib in Lung Cancer
4.
Asymptomatic or Minimally Symptomatic Myelofibrosis
5.
VP Nominee Medical Records Breached; Queen Elizabeth's Cancer; Galaxy Gas Whippets
1.
Unlocking the Potential of Lymphocytes: Exploring the Role of These Immune System Cells
2.
Voices That Heal: Redefining Cancer Care Through Patient Insights and Partnership
3.
CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review
4.
Understanding Colon Cancer: Symptoms, Causes, and Treatment Options
5.
All You Need To Know About Melanoma Maligna: Causes, Symptoms & Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
5.
Navigating the Complexities of Ph Negative ALL - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge